A new study led by Fred Hutch Cancer Center looked at zip codes to assess socioeconomic status and access to bone marrow transplants SAN DIEGO, Calif. — Dec. 8, 2024 — Patients with acute myeloid ...

1.5-year clinical outcomes in patients with triple-mutated AML who were positive and negative for MRD before allo-HSCT. This paper explores the clinical outcomes of allogeneic hematopoietic stem cell ...

Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non–Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial ...

Acute myeloid leukaemia (AML) is a complex and aggressive haematological malignancy that arises from the clonal proliferation of myeloid precursors. It is typified by a marked heterogeneity in ...

Upfront hematopoietic stem cell transplantation (HSCT) is more cost-effective than delayed HSCT for patients with intermediate-risk acute myeloid leukemia in remission, with higher incremental net ...

Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly approved agent for allogeneic hematopoietic stem cell transplantation (allo-HSCT) ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. One important aspect of improving survival ...

Australian researchers have demonstrated that the use of a new, less toxic drug combination after stem cell transplants for leukemia significantly improves patient outcomes post-transplant, reducing ...

SYRACUSE, N.Y. (WSYR-TV) — A Central Square woman is turning one of her hardest battles of her life into a message of hope for others after being diagnosed with a rare and aggressive form of cancer.

When his father was diagnosed with leukaemia in 2025, a 10-year-old Malaysian boy stepped up to be his stem cell donor through a bone marrow transplant. It was the only way doctors said his father ...